Clinical Trial Update: A First-in-Human Study of FID-022 in Solid Tumor Patients

View source ↗

Summary

A first-in-human study of the experimental agent FID-022 in solid tumors is listed, with pancreatic cancer and cancer cachexia as conditions, and the trial is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Cachexia
• Pancreatic Cancer

Drugs mentioned

• FID-022

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Pancreatic Cancer, Cancer Cachexia | Status: RECRUITING